Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
- 2 July 2012
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 28 (1), 61-70
- https://doi.org/10.1002/mds.25108
Abstract
Over the last two decades, significant strides has been made toward acquiring a better knowledge of both the etiology and pathogenesis of Parkinson's disease (PD). Experimental models are of paramount importance to obtain greater insights into the pathogenesis of the disease. Thus far, neurotoxin‐based animal models have been the most popular tools employed to produce selective neuronal death in both in vitro and in vivo systems. These models have been commonly referred to as the pathogenic models. The current trend in modeling PD revolves around what can be called the disease gene‐based models or etiologic models. The value of utilizing multiple models with a different mechanism of insult rests on the premise that dopamine‐producing neurons die by stereotyped cascades that can be activated by a range of insults, from neurotoxins to downregulation and overexpression of disease‐related genes. In this position article, we present the relevance of both pathogenic and etiologic models as well as the concept of clinically relevant designs that, we argue, should be utilized in the preclinical development phase of new neuroprotective therapies before embarking into clinical trials. © 2013 Movement Disorder SocietyKeywords
This publication has 113 references indexed in Scilit:
- Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applicationsMovement Disorders, 2011
- Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceNeurobiology of Disease, 2010
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after EndocytosisNeuron, 2010
- Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synucleinNeuron, 2009
- Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s DiseaseNeurotoxicity Research, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocolParkinsonism & Related Disorders, 2008
- Parkin Protects against Neurotoxicity in the 6-Hydroxydopamine Rat Model for Parkinson's DiseaseMolecular Therapy, 2006
- Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine SystemNeuron, 2000